Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism IL-12p40 inhibitors(Interleukin-12 subunit beta inhibitors), VEGI inhibitors(Tumor necrosis factor superfamily member 15 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Inflammatory Bowel Diseases | Phase 1 | US | 04 Oct 2022 |